Epigenomics (EPGNY) Stock Price, News & Analysis

Company Overview

Epigenomics AG (OTCMKTS: EPGNY) is a molecular diagnostics company focused on the discovery, development and commercialization of epigenetic biomarker assays for early cancer detection. The company’s proprietary technology platform analyzes DNA methylation patterns in circulating cell‐free DNA, aiming to identify and differentiate malignant from benign conditions. Epigenomics’ approach seeks to provide non-invasive, blood-based screening tests that can complement or replace existing methods such as colonoscopy or imaging in certain settings.

The company’s lead diagnostic test, Epi proColon, is a CE-IVD marked blood test for colorectal cancer screening in Europe and was granted FDA approval in the United States in 2016. By targeting a specific methylated gene marker associated with colorectal tumors, Epi proColon offers an alternative for individuals who are reluctant or unable to undergo conventional screening procedures. Beyond its flagship product, Epigenomics is advancing a pipeline of assays for other solid tumors—including lung and pancreatic cancer—through collaborations with academic institutions and industry partners to validate novel methylation signatures.

Founded in 1998 and headquartered in Berlin, Germany, Epigenomics has established a commercial presence in both Europe and North America, with distribution agreements extending into Asia. The company’s leadership team brings together expertise in molecular biology, diagnostics development and regulatory affairs to drive product innovation and market access. Epigenomics continues to invest in research partnerships and clinical studies aimed at expanding the clinical utility of its platform across a broader range of oncology indications.

Key Stats

• Today's Range: $2.39 to $2.39
• 50-Day Range: $2.39 to $2.39
• 52-Week Range: $2.01 to $2.39
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EPGNY Stock Analysis - Frequently Asked Questions

How have EPGNY shares performed this year?

Epigenomics' stock was trading at $2.39 at the beginning of 2025. Since then, EPGNY shares have increased by 0.0% and is now trading at $2.39.

How do I buy shares of Epigenomics?

Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EPGNY
• CIK: N/A
• Web: www.epigenomics.com
• Phone: (493) 024-3450
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A